SHR-2554
As of the edition of 20 October 2026, SHR-2554 is a drug known only by a code name: in active development; acts on EZH2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 18, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Digestive system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EZH2 | Histone-lysine N-methyltransferase EZH2 | Q15910 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 5 | 1 | 0 |
| Phase 2 | 12 | 0 | 9 | 1 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2018 to now |